Literature DB >> 9345359

Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study.

E Sartori1, L Bazzurini, A Gadducci, F Landoni, A Lissoni, T Maggino, P Zola, B La Face.   

Abstract

The purpose of this paper is to retrospectively analyze the clinical and pathological data of 118 cases of uterine carcinosarcoma. Prognostic factors and management were evaluated. chi 2 and log-rank tests were performed. Surgical stage at time of surgery was the most important prognostic factor (P < 0.0001); in stage I-II disease depth of myometrial invasion and lymphatic/vascular space involvement were significantly related to outcome, whereas other factors were not useful. In stage I-II patients postoperative radiation did not improve 5-year disease-free survival. Survival curves in patients with advanced disease treated with cisplatin-containing regimens or with doxorubicin (without cisplatin)-containing regimens were overlapping.

Entities:  

Mesh:

Year:  1997        PMID: 9345359     DOI: 10.1006/gyno.1997.4827

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  22 in total

1.  Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma.

Authors:  Gloria S Huang; Lydia G Chiu; Juliana S Gebb; Marc J Gunter; Paniti Sukumvanich; Gary L Goldberg; Mark H Einstein
Journal:  Gynecol Oncol       Date:  2007-10-23       Impact factor: 5.482

2.  Case report of uterine carcinosarcoma with incisional site recurrence.

Authors:  Rajshree Katke; Dilip Sandipan Nikam; Mehul Bhansali; B K Smruti
Journal:  J Obstet Gynaecol India       Date:  2013-04-11

3.  Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers.

Authors:  Ashley Sinclair Felix; Roslyn A Stone; Robert Bowser; Mamatha Chivukula; Robert P Edwards; Joel L Weissfeld; Faina Linkov
Journal:  Int J Gynecol Cancer       Date:  2011-07       Impact factor: 3.437

4.  MicroRNA signatures differentiate uterine cancer tumor subtypes.

Authors:  Elena S Ratner; David Tuck; Christine Richter; Sunitha Nallur; Rajeshvari M Patel; Vince Schultz; Pei Hui; Peter E Schwartz; Thomas J Rutherford; Joanne B Weidhaas
Journal:  Gynecol Oncol       Date:  2010-06-09       Impact factor: 5.482

5.  Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.

Authors:  Matthew A Powell; Virginia L Filiaci; Peter G Rose; Robert S Mannel; Parviz Hanjani; Koen Degeest; Brigitte E Miller; Nobuyuki Susumu; Frederick R Ueland
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

Review 6.  Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.

Authors:  Khadra Galaal; Esther van der Heijden; Keith Godfrey; Raj Naik; Ali Kucukmetin; Andrew Bryant; Nagindra Das; Alberto D Lopes
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

7.  18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma.

Authors:  Kung-Chu Ho; Chyong-Huey Lai; Tzu-I Wu; Koon-Kwan Ng; Tzu-Chen Yen; Gigin Lin; Ting-Chang Chang; Chun-Chieh Wang; Swei Hsueh; Huei-Jean Huang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-19       Impact factor: 9.236

Review 8.  Uterine sarcoma 2008.

Authors:  Jeff F Lin; Brian M Slomovitz
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

9.  Evaluation of postoperative chemotherapy in patients with uterine carcinosarcoma: a retrospective survey of the Tohoku Gynecologic Cancer Unit.

Authors:  Ai Otsuki; Takeo Otsuki; Hideki Tokunaga; Hitoshi Niikura; Satoru Nagase; Takashi Sugiyama; Masafumi Toyoshima; Hiroki Utsunomiya; Yoshihito Yokoyama; Hideki Mizunuma; Naoki Sato; Yukihiro Terada; Tadahiro Shoji; Toru Sugiyama; Kenji Nakahara; Tsuyoshi Ohta; Hidekazu Yamada; Toru Tase; Hiroshi Nishiyama; Keiya Fujimori; Tadao Takano; Fumiaki Takahashi; Yoh Watanabe; Nobuo Yaegashi
Journal:  Int J Clin Oncol       Date:  2014-07-18       Impact factor: 3.402

Review 10.  Treatment of early uterine sarcomas: disentangling adjuvant modalities.

Authors:  Flora Zagouri; Athanasios-Meletios Dimopoulos; Stelios Fotiou; Vassilios Kouloulias; Christos A Papadimitriou
Journal:  World J Surg Oncol       Date:  2009-04-08       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.